REVLIMID (lenalidomide) by Bristol Myers Squibb. Approved for thalidomide analog [epc]. First approved in 2005.
Drug data last refreshed 16h ago · AI intelligence enriched 2mo ago
REVLIMID (lenalidomide) is an oral thalidomide analog small molecule used in hematologic and solid tumor malignancies. It functions as an immunomodulatory agent, enhancing T-cell proliferation and NK cell activity while demonstrating anti-angiogenic and anti-proliferative properties. Patient populations include those with multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma.
With 1.5 years to LOE and $3.9B in annual spending, the brand faces significant defensive challenges; expect increased focus on manufacturing efficiency, compliance, and transition planning across commercial teams.
Thalidomide Analog
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Study to Evaluate the Feasibility and Safety of Autologous Cytokine-Induced Killer Cells (CIK_D332) in Combination With Tafasitamab and Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Zilovertamab Vedotin and Lenalidomide (ZiVLen) Therapy for Relapsed/Refractory Peripheral T-Cell Lymphoma
A Trial Comparing Ramantamig and Daratumumab (Ramantamig-D) Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible
Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell Therapy
Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
Worked on REVLIMID at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moPatent cliff in ~2 years — expect lifecycle management and generic defense hiring
$3.9B Medicare spend — this is a commercially significant brand
Working on REVLIMID offers 505 linked career opportunities across defensive and operational functions. Roles concentrate in manufacturing (cost/supply optimization), pharmacovigilance (sustained safety monitoring), and regulatory affairs (LOE risk mitigation), signaling a mature-product career trajectory focused on operational excellence rather than growth.
505 open roles linked to this drug